341 related articles for article (PubMed ID: 25314935)
1. Fluorescent biosensors for drug discovery new tools for old targets--screening for inhibitors of cyclin-dependent kinases.
Prével C; Kurzawa L; Van TN; Morris MC
Eur J Med Chem; 2014 Dec; 88():74-88. PubMed ID: 25314935
[TBL] [Abstract][Full Text] [Related]
2. Fluorescent biosensors - probing protein kinase function in cancer and drug discovery.
Morris MC
Biochim Biophys Acta; 2013 Jul; 1834(7):1387-95. PubMed ID: 23376184
[TBL] [Abstract][Full Text] [Related]
3. Fluorescent biosensors for high throughput screening of protein kinase inhibitors.
Prével C; Pellerano M; Van TN; Morris MC
Biotechnol J; 2014 Feb; 9(2):253-65. PubMed ID: 24357625
[TBL] [Abstract][Full Text] [Related]
4. Fluorescent protein biosensor for probing CDK/cyclin activity in vitro and in living cells.
Van TN; Pellerano M; Lykaso S; Morris MC
Chembiochem; 2014 Oct; 15(15):2298-305. PubMed ID: 25209885
[TBL] [Abstract][Full Text] [Related]
5. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
6. Targeting Conformational Activation of CDK2 Kinase.
Pellerano M; Tcherniuk S; Perals C; Ngoc Van TN; Garcin E; Mahuteau-Betzer F; Teulade-Fichou MP; Morris MC
Biotechnol J; 2017 Aug; 12(8):. PubMed ID: 28430399
[TBL] [Abstract][Full Text] [Related]
7. Fluorescent peptide biosensor for probing the relative abundance of cyclin-dependent kinases in living cells.
Kurzawa L; Pellerano M; Coppolani JB; Morris MC
PLoS One; 2011; 6(10):e26555. PubMed ID: 22028905
[TBL] [Abstract][Full Text] [Related]
8. High throughput screens yield small molecule inhibitors of Leishmania CRK3:CYC6 cyclin-dependent kinase.
Walker RG; Thomson G; Malone K; Nowicki MW; Brown E; Blake DG; Turner NJ; Walkinshaw MD; Grant KM; Mottram JC
PLoS Negl Trop Dis; 2011 Apr; 5(4):e1033. PubMed ID: 21483720
[TBL] [Abstract][Full Text] [Related]
9. Novel potent pharmacological cyclin-dependent kinase inhibitors.
Węsierska-Gądek J; Chamrád I; Kryštof V
Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
[TBL] [Abstract][Full Text] [Related]
10. Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.
Peyressatre M; Prével C; Pellerano M; Morris MC
Cancers (Basel); 2015 Jan; 7(1):179-237. PubMed ID: 25625291
[TBL] [Abstract][Full Text] [Related]
11. Peptides or small molecules? Different approaches to develop more effective CDK inhibitors.
Cirillo D; Pentimalli F; Giordano A
Curr Med Chem; 2011; 18(19):2854-66. PubMed ID: 21651493
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinases: bridging their structure and function through computations.
De Vivo M; Bottegoni G; Berteotti A; Recanatini M; Gervasio FL; Cavalli A
Future Med Chem; 2011 Sep; 3(12):1551-9. PubMed ID: 21882947
[TBL] [Abstract][Full Text] [Related]
13. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
Nandha Premnath P; Craig S; McInnes C
J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
[TBL] [Abstract][Full Text] [Related]
14. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
Kalra S; Joshi G; Munshi A; Kumar R
Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
[TBL] [Abstract][Full Text] [Related]
15. Selectivity and potency of cyclin-dependent kinase inhibitors.
Sridhar J; Akula N; Pattabiraman N
AAPS J; 2006 Mar; 8(1):E204-21. PubMed ID: 16584130
[TBL] [Abstract][Full Text] [Related]
16. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
Santo L; Siu KT; Raje N
Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development.
Waters NC; Geyer JA
Expert Opin Ther Targets; 2003 Feb; 7(1):7-17. PubMed ID: 12556199
[TBL] [Abstract][Full Text] [Related]
18. Recent advances on CDK inhibitors: An insight by means of in silico methods.
Tutone M; Almerico AM
Eur J Med Chem; 2017 Dec; 142():300-315. PubMed ID: 28802482
[TBL] [Abstract][Full Text] [Related]
19. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity.
Premnath PN; Craig SN; Liu S; Anderson EL; Grigoroudis AI; Kontopidis G; Perkins TL; Wyatt MD; Pittman DL; McInnes C
J Med Chem; 2015 Jan; 58(1):433-42. PubMed ID: 25454794
[TBL] [Abstract][Full Text] [Related]
20. Designing inhibitors of cyclin-dependent kinases.
Hardcastle IR; Golding BT; Griffin RJ
Annu Rev Pharmacol Toxicol; 2002; 42():325-48. PubMed ID: 11807175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]